Similarly, the BROCADE3 phase III clinical trial compared veliparib versus placebo in combination with carboplatin and paclitaxel, and continued as monotherapy if carboplatin and paclitaxel were discontinued before progression, in patients with HER2-negative advanced breast cancer and germline BRCA1 or BRCA2 mutation. This evidence concerns the gene BRCA1 and breast cancer.